A novel RNA-guided platform for sequence-specific cell reprogramming
A novel RNA-guided platform for sequence-specific cell reprogramming
批准号:
8609325
负责人:
Lei Stanley Qi
金额:
$39.29万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-19 至 2018-08-31
关键词:
AddressAdverse effectsAlgorithmsBacteriaBase PairingBedsBindingBiological AssayCell TherapyCellsDNADNA BindingDNA-Binding ProteinsDerivation procedureDevelopmentDiseaseEngineeringEpigenetic ProcessEscherichia coliFluorescenceGene ActivationGene ExpressionGene Expression RegulationGene OrderGenerationsGenesGeneticGenetic ProgrammingGenetic TranscriptionGenomeGenomicsGoalsGuide RNAHumanImmuneImmune systemImmunityKineticsLibrariesLightMammalian CellMeasuresMediatingMethodsModelingMolecularPathway interactionsPhysiologyProteinsRNARNA InterferenceRNA libraryRegulationRepressionResearchSiteSpecificitySystemT-LymphocyteTestingTherapeuticTissuesTranscription CoactivatorTranscriptional ActivationTranscriptional RegulationWorkZinc Fingersbasecellular engineeringdesigngene repressiongenome-widehistone modificationhuman BCAR1 proteininduced pluripotent stem cellinterestlight gatedmathematical modelnovelnucleaseoptogeneticsprogramspublic health relevancerepairedresearch studystem cell differentiationtissue regenerationtooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Genetic reprogramming of cell fate and identity is a promising strategy for cell-based therapies and tissue
regeneration. In particular, targeted manipulation of a few genes has been shown as a useful method for
induced pluripotent stem (iPS) cell derivation, stem cell differentiation, and T-cell reengineering. Though rapid
progress has been made, current methods for targeted genome manipulation are very inefficient and require
many accessory factors, limiting their utility for effective cell reprogramming to control different levels of
regulation and to coordinate the kinetic expression of large numbers of genes. The major goal of the research
is to develop a novel modular and programmable RNA-guided platform that can be used to target multiple
genes in a genome for transcriptional or epigenetic regulation, and to exploit its applications for iPS cell
reprogramming and potentially other cell-based therapeutic approaches. The proposed platform is built on my
recently demonstrated CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) interference
(CRISPRi) system derived from the bacterial immune pathway, which is an RNA-guided method for
transcriptional silencing of arbitrary genes in diverse host cells. The method requires only a single modified
Cas protein (catalytically inactive) and a designed small guide RNA with a 20-basepair complementary region
to any gene of interest, without genetically altering the target locus. To further develop the system as a novel
cell-reprogramming platform, I will first perform high-throughput characterization experiments in bacteria as a
model to quantify the determinants of RNA-guided regulatory efficiency and specificity. Mathematical models
will be developed and used for the rational design of large RNA libraries for efficient and specific genome
targeting. Second, to develop a programmable platform for various regulatory functions, I will extend the
CRISPRi system as a modular DNA-binding system for use in mammalian cells. The system will be combined
with protein effectors for different types of genome-scale targeted regulations, including transcription activation,
transcription silencing, and heritable histone modification. I will also introduce the ability to regulate these
functions using light, through the use of optogenetically controlled protein interactions. Third, as a test bed, I
will focus on using the programmable CRISPRi platform as an alternative and perhaps easier way to generate
iPS cells. I will create light-gated transcription circuits to precisely control the expression program of
endogenous transcription factors that are known to be important for iPS cell reprogramming. I will also use the
CRISPRi platform to target and modify epigenetic regulation of these factors, and study if regulating epigenetic
marks could achieve more efficient, more stable, and safer reprogramming. Together, these aims will address
a critical barrier for cell reprogramming by providing a novel RNA-guided platform for sequence-specific
regulation of multiple genes for various types of regulation. Further, the proposal will provide a novel
technological basis for constructing gene circuits to coordinate multiple genes for iPS cell generation, which is
also directly applicable to other cell reprogramming applications such as stem cell differentiation and T-cell
engineering.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of multi-color 3D super-localization LiveFISH and LiveFISH PAINT to investigate the chromatin dynamics at any genomic scale
-
批准号:10725002
-
项目类别:
-
资助金额:$42.04万
-
财政年份:2023
-
负责人:Lei Stanley Qi
-
依托单位:
Manipulating and Interrogating Spatial Transcriptomics
-
批准号:10702050
-
项目类别:
-
资助金额:$108.08万
-
财政年份:2023
-
负责人:Lei Stanley Qi
-
依托单位:
A Cas13d-based screening approach to engineer exhaustion-resistant CAR T cells
-
批准号:10431227
-
项目类别:
-
资助金额:$18.29万
-
财政年份:2022
-
负责人:Lei Stanley Qi
-
依托单位:
A Cas13d-based screening approach to engineer exhaustion-resistant CAR T cells
-
批准号:10571868
-
项目类别:
-
资助金额:$21.61万
-
财政年份:2022
-
负责人:Lei Stanley Qi
-
依托单位:
High resolution dissection of oncogene enhancer networks via CRISPR screening and live-cell imaging.
-
批准号:10522013
-
项目类别:
-
资助金额:$43.98万
-
财政年份:2022
-
负责人:Lei Stanley Qi
-
依托单位:
Probing relationships between DNA methylation and cellular senescence with high-throughput CRISPR-based epigenetic editing
-
批准号:10593233
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2022
-
负责人:Lei Stanley Qi
-
依托单位:
High resolution dissection of oncogene enhancer networks via CRISPR screening and live-cell imaging.
-
批准号:10671756
-
项目类别:
-
资助金额:$44.24万
-
财政年份:2022
-
负责人:Lei Stanley Qi
-
依托单位:
Examining COVID-19 in Down Syndrome Patients Using Human iPSC-Derived Organoids
-
批准号:10241207
-
项目类别:
-
资助金额:$66.88万
-
财政年份:2021
-
负责人:Lei Stanley Qi
-
依托单位:
Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
-
批准号:10518663
-
项目类别:
-
资助金额:$68.39万
-
财政年份:2018
-
负责人:Lei Stanley Qi
-
依托单位:
Human iPSCs for Elucidating Intercellular Crosstalk Signaling in DCM - Diversity Supplement
-
批准号:10730997
-
项目类别:
-
资助金额:$3.39万
-
财政年份:2018
-
负责人:Lei Stanley Qi
-
依托单位:
Human iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated Cardiomyopathy
-
批准号:10852761
-
项目类别:
-
资助金额:$9.2万
-
财政年份:2018
-
负责人:Lei Stanley Qi
-
依托单位:
Human iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated Cardiomyopathy
-
批准号:10444652
-
项目类别:
-
资助金额:$69.69万
-
财政年份:2018
-
负责人:Lei Stanley Qi
-
依托单位:
Elucidating CHD in Down Syndrome with Cardiac Organoids and 3D Genome Architecture
-
批准号:10852469
-
项目类别:
-
资助金额:$38.58万
-
财政年份:2018
-
负责人:Lei Stanley Qi
-
依托单位:
Human iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated Cardiomyopathy
-
批准号:10627921
-
项目类别:
-
资助金额:$69.06万
-
财政年份:2018
-
负责人:Lei Stanley Qi
-
依托单位:
Genome Editing of Human iPSCs to Study Inherited Hypertrophic Cardiomyopathy
-
批准号:10454967
-
项目类别:
-
资助金额:$66.97万
-
财政年份:2015
-
负责人:Lei Stanley Qi
-
依托单位:
Genome Editing of Human iPSCs to Study Inherited Hypertrophic Cardiomyopathy
-
批准号:9814475
-
项目类别:
-
资助金额:$68.85万
-
财政年份:2015
-
负责人:Lei Stanley Qi
-
依托单位:
Genome Editing of Human iPSCs to Study Inherited Hypertrophic Cardiomyopathy
-
批准号:10213111
-
项目类别:
-
资助金额:$66.97万
-
财政年份:2015
-
负责人:Lei Stanley Qi
-
依托单位:
A novel RNA-guided platform for sequence-specific cell reprogramming
-
批准号:8928376
-
项目类别:
-
资助金额:$33.32万
-
财政年份:2013
-
负责人:Lei Stanley Qi
-
依托单位:
A novel RNA-guided platform for sequence-specific cell reprogramming
-
批准号:9349361
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2013
-
负责人:Lei Stanley Qi
-
依托单位:
A novel RNA-guided platform for sequence-specific cell reprogramming
-
批准号:8914999
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2013
-
负责人:Lei Stanley Qi
-
依托单位:
海外基金